Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug-Eluting Stents Could Experience Blockage From New Safety Data

This article was originally published in The Gray Sheet

Executive Summary

Public questions concerning the safety of the Taxus andCypher drug-eluting stents increased measurably last week amid results reported at a major cardiology conference and a disclosure by Boston Scientific that Taxus is associated with an increased risk of blood clots

You may also be interested in...



Drug-Eluting-Stent Market Penetration At Nadir? Rebound Forecast At TCT

U.S. drug-eluting-stent market penetration reached an all-time low in September, but clinicians meeting last week in Washington, D.C., are confident new data will help to reverse the trend that began just over a year ago

Drug-Eluting-Stent Market Penetration At Nadir? Rebound Forecast At TCT

U.S. drug-eluting-stent market penetration reached an all-time low in September, but clinicians meeting last week in Washington, D.C., are confident new data will help to reverse the trend that began just over a year ago

Vienna Meeting Goes Relatively Smoothly For Drug-Eluting Stent Makers

Drug-eluting stent manufacturers did not have to answer to any surprise negative results at the European Society of Cardiology conference in Vienna this year and, in fact, got some good news from an ongoing registry

Related Content

UsernamePublicRestriction

Register

OM013133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel